Work

STL1267 inhibits myofibroblast differentiation in a TGFβ1-driven human lung fibroblast model

Year: 2026

Type: article

Abstract: This study introduces a novel in vitro adenovirus-based model of persistent TGFβ1 signaling in normal human lung fibroblasts to mimic chronic fibrosis. Using this model, we show that the next-generation REV-ERBα agonist STL1267 robustly inhibits myofibroblast differentiation and ECM gene expression. STL1267 outperforms Food and Drug Administration-approved antifibrotic drugs and modulates immune and circadian signaling pathways, supporting its potential as a promising circadian-based therapeutic strategy for pulmonary fibrosis.

Source: American Journal of Physiology-Cell Physiology

DOI: 10.1152/ajpcell.00561.2025

Authors: Chandrashekhar Prasad, Steven K. Huang, Thomas P. Burris, Isaac Kirubakaran Sundar

Institutions: University of Kansas Medical Center, University of Michigan, University of Florida

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green